French biotech ImCheck Therapeutics has announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation (ODD) to its lead program, ICT01, a humanized anti-butyrophilin 3A (BTN3A ...

Marseille, France Monday, July 21, 2025, 12:00 Hrs [IST] ...

ImCheck Therapeutics just raised $103 million to treat multiple forms of cancer. The company is working on one of the fastest-growing ideas in cancer research: gamma-delta T cells.

ImCheck Therapeutics’ contribution is a type of drug that could bring advantages over the first generation of cancer immunotherapies. Now the biotech has €96M that will help continue clinical ...

ImCheck Therapeutics is designing and developing a new generation of immunotherapeutic antibodies positioned at the crossroads of two high-potential immunological fields: ...

ImCheck Therapeutics raises €20 Million and appoints its CEO Emerging leader in immuno-oncology accelerates its development programs and prepares for entry into the clinic Marseille, France, May ...

MARSEILLE, France, Aug. 1, 2019 /PRNewswire/ -- ImCheck Therapeutics, a biotech company on the cutting edge of the next wave of immunotherapies against cancer and autoimmune diseases, announced ...

Imcheck Therapeutics SAS’s gamma-delta T-cell activating antibody has become a poster child for the French government’s plan to reduce dependence on imports of biopharmaceuticals by directly ...

ImCheck Therapeutics Appoints Dr. Loui Madakamutil, Noted Expert in Immunology and Autoimmune Diseases, as Chief Scientific Officer Marseille, France, April 15, 2021 – ImCheck Therapeutics today ...

First hire in the US will support growing global business development activities Marseille, France, July 9, 2020 – ImCheck Therapeutics today announced the appointment of Claude Knopf as Chief ...

ImCheck’s ICT01 Receives FDA Orphan Drug Designation for Treatment of Acute Myeloid Leukemia . Clinical data showing unprecedented remission rates in newly diagnosed AML patient ...